Washington University: Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials

(marketscreener.com) Data from study using Guardant360® blood test show Black patients with PIK3CA mutations in advanced breast cancer were less likely than White patients to be enrolled in clinical trials and receive targeted therapy Study is part of collaboration between Guardant Health and Multicenter Precision Medicine Academic Consortium using liquid...https://www.marketscreener.com/quote/stock/GUARDANT-HEALTH-INC-46434671/news/Guardant-Health-and-Washington-University-to-present-study-at-2024-ASCO-meeting-highlighting-utility-46888382/?utm_medium=RSS&utm_content=20240603